Ananda Pharma, a UK-based pharmaceutical company, has commenced a pivotal Phase 2 clinical trial in the United Kingdom, dosing the first patient in its ACTiON study. This trial is evaluating MRX1, a proprietary oral solution containing cannabidiol (CBD), for its potential in managing chemotherapy-induced peripheral neuropathy (CIPN), a severe and often lingering side effect of cancer treatment for which current effective therapies are limited.
Understanding Chemotherapy-Induced Peripheral Neuropathy (CIPN)
Chemotherapy-induced peripheral neuropathy (CIPN) represents a significant challenge in oncology supportive care. This debilitating condition arises as a direct consequence of certain neurotoxic chemotherapy agents, leading to damage to the peripheral nerves. Patients frequently experience persistent numbness, tingling sensations, and considerable pain, predominantly in their hands and feet. These symptoms often emerge during chemotherapy treatment and can, for a substantial number of individuals, persist long after the cessation of their cancer therapy.
The impact of CIPN extends beyond mere discomfort, profoundly affecting a patient’s quality of life and, critically, their treatment trajectory. The severity of these neurological symptoms can compel oncologists to adjust or even halt chemotherapy regimens prematurely. This clinical dilemma is particularly problematic as it may compromise treatment efficacy, potentially increasing the risk of disease progression or requiring extended treatment durations. A systematic review published in 2014 by Seretny et al. indicated that approximately 67% or more of patients undergoing neurotoxic chemotherapy will experience CIPN, underscoring the widespread nature and urgency of this unmet medical need.
MRX1: Ananda Pharma's CBD-Based Solution
At the heart of the ACTiON trial is MRX1, Ananda Pharma's investigational CBD-based oral solution. This product features a patent-pending formulation designed to deliver cannabidiol, a non-intoxicating compound derived from the cannabis plant, in a controlled manner. Cannabidiol has garnered considerable scientific interest globally for its complex interactions within the human endocannabinoid system, which plays a role in regulating various physiological processes, including pain perception.
The development of MRX1 has progressed through rigorous early-stage clinical evaluation. Ananda Pharma completed a Phase 1 pharmacokinetic trial for MRX1 earlier in the year, involving 20 participants. This initial study successfully confirmed a clean safety profile for the solution, providing a crucial foundation for its advancement into more extensive Phase 2 trials. The manufacturing of the MRX1 investigational product was concluded in 2025, with delivery to the University of Edinburgh central pharmacy occurring on 6 June 2026, paving the way for patient enrolment and dosing.
The ACTiON Trial and NIHR Backing
The ACTiON study is a Phase 2 clinical trial being conducted in the United Kingdom, led by Professor Marie Fallon at the prestigious University of Edinburgh. This research initiative has received significant backing from the National Institute for Health and Care Research (NIHR), a prominent funding body within the UK's health research landscape. The NIHR awarded the ACTiON study an Efficacy and Mechanism Evaluation (EME) grant, a form of non-dilutive funding that is only granted after a stringent process of independent scientific scrutiny and peer review.
The involvement of the NIHR carries substantial weight beyond its financial contribution. It serves as a clear signal that the research question being addressed—the potential of MRX1 for CIPN—has undergone thorough independent assessment and is deemed both scientifically robust and medically justified. This level of endorsement provides a strong indicator of the trial's credibility and its potential to contribute meaningfully to medical science. The first patient received dosing in the ACTiON trial around a week after the investigational product arrived at the University of Edinburgh, marking a critical milestone in the study's progression.
Ananda Pharma's Chief Executive Officer, Melissa Sturgess, expressed the company's enthusiasm regarding this development. As reported by Business of Cannabis, Sturgess stated, “We are delighted to see the first patient dosed in the CIPN trial using our patent pending MRX1 formulation. This is gold standard work and we are honoured to be part of it.”
For additional context on the broader landscape of medical cannabis developments in the UK, readers may find our article on Rua Bioscience's UK medical cannabis export deal insightful.
Ananda Pharma's Strategic Focus on Pain Indications
The initiation of the ACTiON trial underscores a significant strategic pivot for Ananda Pharma, a direction the company accelerated in the preceding year. This reorientation saw the company exit a previously NIHR-funded epilepsy trial and make a deliberate move away from public markets. This strategic decision was aimed at concentrating its capital and resources squarely on advancing MRX1's pipeline of pain-focused indications.
The ACTiON trial is not the sole clinical programme currently underway for Ananda Pharma. It runs concurrently with the ENDOCAN trial, another Phase 2 study that is investigating MRX1 for its potential in addressing endometriosis-associated pain. The simultaneous progression of these two late-stage clinical programmes positions Ananda Pharma to potentially receive Phase 2 readouts from distinct pain indications within a similar timeframe. This parallel development strategy highlights the company's commitment to exploring the therapeutic potential of its CBD-based solution across a range of challenging pain conditions, aiming to provide novel options for patients where current treatments are insufficient. The broader implications of such research initiatives are also explored in our piece on federal agencies partnering for psychedelic research, demonstrating a wider trend in novel therapeutic exploration.
Looking Ahead: The Potential Impact of CBD Research
The ongoing research into CBD-based solutions like MRX1 represents a crucial frontier in cannabis science. While cannabis and its constituents have been used anecdotally for centuries, rigorous clinical trials are essential to establish their safety and efficacy for specific medical conditions. Trials such as ACTiON contribute significantly to the growing body of scientific evidence, helping to delineate the precise roles and benefits of cannabinoids in a medical context.
The successful completion of Phase 2 trials, should they demonstrate positive outcomes, would be a critical step towards potentially bringing new therapeutic options to patients suffering from conditions like CIPN. The scientific community and patient advocacy groups worldwide are closely watching these developments, as they hold the promise of addressing significant unmet medical needs through innovative cannabis-derived medicines.
It is important for readers to note that while research into cannabis-based medicines is advancing globally, the legal status and availability of such products vary widely by country and jurisdiction. Individuals should always confirm the current laws and regulations pertinent to cannabis and its derivatives in their specific location.
Frequently Asked Questions
What is the ACTiON trial investigating?
The ACTiON trial is a Phase 2 clinical study in the UK evaluating Ananda Pharma's MRX1, a CBD-based oral solution, for its potential in managing chemotherapy-induced peripheral neuropathy (CIPN).
What is chemotherapy-induced peripheral neuropathy?
CIPN is a debilitating nerve damage condition caused by certain chemotherapy treatments, leading to symptoms like numbness, tingling, and pain, often in the hands and feet.
Who is funding the ACTiON trial?
The ACTiON trial is funded by the National Institute for Health and Care Research (NIHR) in the United Kingdom through an Efficacy and Mechanism Evaluation (EME) grant.
What is MRX1?
MRX1 is Ananda Pharma's proprietary CBD-based oral solution, which has a patent-pending formulation and completed a Phase 1 safety trial earlier this year.
Why is NIHR funding significant for this research?
NIHR funding indicates that the research question has undergone independent peer review and is considered scientifically sound and medically warranted within the UK context.
Are there other trials for MRX1 underway?
Yes, Ananda Pharma is also running the ENDOCAN trial, a parallel Phase 2 study evaluating MRX1 for endometriosis-associated pain.
